X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: New drug wonders! - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Sep 21, 2005

    Pharma: New drug wonders!

    Until January 2005, since India had recognized process patents, it resulted in domestic pharma companies becoming an expert in 'reverse engineering' of products. However, a major development took place in the Indian pharmaceutical market, when the product patent law was introduced with effect from January 1, 2005. This means that domestic majors will have to focus on new drug discovery research in the long term if they want to benchmark themselves against the global pharma majors. In this article, we take a look at what Indian companies are doing on the drug discovery front.

    What does new drug discovery involve?
    On the discovery of a molecule, the US FDA grants a patent for the molecule for a period of 20 years. New drug discovery involves various steps, which starts with the building up of a new molecule. This is followed by synthesis of the molecule and the conduct of pre-clinical testing (laboratory and animal). After this, the molecule enters the clinical trials stage, which comprises of 3 phases - I, II and III. In Phase I, studies are conducted on around 20 to 80 healthy volunteers to determine safety and dosage. In Phase II and III, a larger patient population is enrolled for the purpose of determining efficacy and side effects and also to monitor the adverse reactions of long-term use. After successful conduct of these trials, a pharma company applies for US FDA approval followed by additional post-marketing testing.

    This entire process takes around 10 to 12 years of the patented life of the molecule. Which means that the remaining 8 to 10 years of the patented drug is called the 'commercial life' of the drug. Investment in launching a new product could be anywhere between US$ 400 m to US$ 800 m.

    Global perspective
    In the global pharmaceutical market, pharma behemoths such as Pfizer, GlaxoSmithKline, Sanofi-aventis etc. have been the pioneers in new product launches, which has resulted in them being labeled as 'innovators'. It must be noted that patented products enjoy a significant premium in terms of pricing, which more than makes up for the costs involved in drug discovery. Blockbuster drugs for instance generate revenues to the tune of US$ 1 bn annually. This translates into US$ 10 bn for the 10 years of its commercial life during which it enjoys a patent, compared to around US$ 800 m that is incurred on research!

    As far as the top 10 products in the global pharmaceutical market are concerned, Pfizer, the largest pharma company in the world, leads the pack with 2 blockbuster drugs 'Lipitor' (US$ 12 bn in revenues in CY04) and 'Norvasc' (US$ 4.8 bn in revenues in CY04) under its belt. Other products in the top 10 include Merck's 'Zocor' (US$ 5.9 bn in revenues in CY04), Sanofi-aventis' 'Plavix' (US$ 5 bn in revenues in CY04), Eli Lilly's 'Zyprexa' (US$ 4.8 bn in revenues in CY04) amongst others.

    Indian scenario
    Domestic pharma majors such as Ranbaxy and Dr.Reddy's have been the forerunners as far as drug discovery research in India is concerned. Currently, Dr.Reddy' has 5 molecules undergoing Phase I and Phase II clinical trials. These are in the areas of oncology (anti-cancer) and metabolic disorders. Ranbaxy meanwhile has 2 molecules in Phase II clinical trials - its bronchial asthma molecule RBx 7796 and its Urology-BPH molecule RBx 2258.

    Wockhardt has also identified new drug discovery as one of its growth drivers going forward. The company currently has 5 molecules in the pipeline in the anti-infectives segment, including its molecule WCK 771 undergoing Phase II clinical trials. Nicholas Piramal's anti-cancer molecule recently entered Phase I clinical trials. All these initiatives could translate into potential revenue generators in the long term.

    Looking aheadů
    Despite the initiatives taken by the domestic pharma industry on the drug discovery front, it is early days yet. A new patented drug from a domestic pharma company's stable will probably not see the light of day for the next 4 to 5 years or so. Also, a domestic pharma company may not have the resources to conduct the clinical trials all the way through, keeping in mind the cost involved. This means that they will have to rely on out-licensing the molecule to a global pharma major. However, despite hiccups, domestic companies have to be acknowledged for taking major strides in the area of new drug discovery. Though not in the medium term, efforts by these companies could turn into global opportunities in the long term.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: New drug wonders!". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 17, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS